Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies
Diabetes mellitus is a pathology with increasing frequency in society, being one of the main causes of death worldwide. For this reason, new therapeutic targets have been studied over the years. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme responsible for reducing cortisone to its...
Saved in:
| Published in | Scientia pharmaceutica Vol. 89; no. 1; p. 5 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
MDPI AG
01.01.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2218-0532 0036-8709 2218-0532 |
| DOI | 10.3390/scipharm89010005 |
Cover
| Abstract | Diabetes mellitus is a pathology with increasing frequency in society, being one of the main causes of death worldwide. For this reason, new therapeutic targets have been studied over the years. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme responsible for reducing cortisone to its active form cortisol, which can lead to metabolic changes such as insulin resistance and hyperglycemia. Therefore, 11β-HSD1 inhibition may offer a new therapeutic approach for type 2 diabetes mellitus. This work intends to systematically review the available scientific evidence on this subject. For this, a search was conducted in three databases and 15 clinical and in vivo preclinical studies were included in this review. Despite the high inhibitory and selectivity levels achieved with several molecules and the demonstrated clinical efficacy in diabetes treatment, no phase III clinical trials have yet been conducted. This is important because the long-term effects of 11β-HSD1 inhibitors including the consequences in hypothalamic–pituitary–adrenal axis must be evaluated. However, this enzyme remains a promising target for drug development, including due to its effectiveness in controlling various factors that constitute the metabolic syndrome and its potential for multiple indications in patients with diabetes, including wound healing and weight loss. |
|---|---|
| AbstractList | Diabetes mellitus is a pathology with increasing frequency in society, being one of the main causes of death worldwide. For this reason, new therapeutic targets have been studied over the years. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme responsible for reducing cortisone to its active form cortisol, which can lead to metabolic changes such as insulin resistance and hyperglycemia. Therefore, 11β-HSD1 inhibition may offer a new therapeutic approach for type 2 diabetes mellitus. This work intends to systematically review the available scientific evidence on this subject. For this, a search was conducted in three databases and 15 clinical and in vivo preclinical studies were included in this review. Despite the high inhibitory and selectivity levels achieved with several molecules and the demonstrated clinical efficacy in diabetes treatment, no phase III clinical trials have yet been conducted. This is important because the long-term effects of 11β-HSD1 inhibitors including the consequences in hypothalamic–pituitary–adrenal axis must be evaluated. However, this enzyme remains a promising target for drug development, including due to its effectiveness in controlling various factors that constitute the metabolic syndrome and its potential for multiple indications in patients with diabetes, including wound healing and weight loss. |
| Author | Silvestre, Samuel Monteiro, Cristina Almeida, Cristiana |
| Author_xml | – sequence: 1 givenname: Cristiana surname: Almeida fullname: Almeida, Cristiana – sequence: 2 givenname: Cristina orcidid: 0000-0002-5225-6222 surname: Monteiro fullname: Monteiro, Cristina – sequence: 3 givenname: Samuel orcidid: 0000-0003-4297-5108 surname: Silvestre fullname: Silvestre, Samuel |
| BookMark | eNp1kc9uEzEQxi1UJNrCnaNfYMH2rte7xyoBGqmIihau1qw9Tlxt7Mh2WnLjIXgIzn2QPgRPwoZQCVXiNKNv9P3m3wk5CjEgIa85e1PXPXubjd-sIK27nnHGmHxGjoXgXcVkLY7-yV-Qk5xvGGt5w9Ux-bkIKz_4ElOm0VHOH-6r851N8dsuF0zRWzrH1V5YYoCM9Hq3QcopZHoZC4biYaTztF1m6mI6VAWdexiwYKYfcRx92eZf33-c0as9cg3FG_oZbz3e7TvORh-8mSAQLF0E-tXfRnqZ0DzqV2VrPeaX5LmDMeOrv_GUfHn_7np2Xl18-rCYnV1Uppa8VMYZGJQwIIyzg1SNMi2YBi2XrRk628uWM-XYdA_DhGkG0bBOOYXQGYWyrk_J4sC1EW70Jvk1pJ2O4PUfIaalhjStMKLGXlrZiNY1ddewFjreN4OdWroeRaeGidUeWCbFnBM6bXyZ9o-hJPCj5kzvf6ef_m4ysifGx0H-a_kNh3alDw |
| CitedBy_id | crossref_primary_10_1016_j_ejphar_2025_177272 crossref_primary_10_3390_nu15071734 crossref_primary_10_1139_cjpp_2021_0400 crossref_primary_10_1002_biof_1793 crossref_primary_10_3390_compounds4010002 crossref_primary_10_3390_ijms26030909 crossref_primary_10_53879_id_60_09_13729 crossref_primary_10_3390_nu16111638 crossref_primary_10_1111_joim_13741 crossref_primary_10_1038_s41386_021_01111_5 crossref_primary_10_3390_ijms25168731 crossref_primary_10_7570_jomes23080 crossref_primary_10_52794_hujpharm_1356537 crossref_primary_10_1007_s40200_023_01191_8 crossref_primary_10_22141_2224_0721_20_4_2024_1406 crossref_primary_10_3390_jcm12062152 |
| Cites_doi | 10.1172/JCI64162 10.1515/hmbci-2013-0015 10.1111/dom.12635 10.1007/978-3-642-17214-4_6 10.2337/dc20-S002 10.1002/cpdd.5 10.1186/2050-6511-15-43 10.1016/j.diabres.2019.107785 10.1111/j.1463-1326.2010.01305.x 10.5483/BMBRep.2013.46.12.248 10.1155/2013/427640 10.1038/nrendo.2017.151 10.1016/j.bmcl.2017.07.043 10.1002/cpdd.292 10.1016/j.ejphar.2018.08.005 10.1111/j.1476-5381.2012.01911.x 10.1210/jc.2016-2069 10.1111/j.1365-2265.2005.02412.x 10.1210/jc.2009-1412 10.2427/5768 10.1210/jc.2002-021194 10.1371/journal.pone.0025039 10.1016/j.ejphar.2014.10.053 10.1007/s40265-013-0112-5 10.1016/j.ejphar.2015.10.042 10.1530/JME-13-0177 10.1016/B978-0-08-102922-0.00004-3 10.1016/j.ejmech.2014.03.012 10.1021/acs.jmedchem.7b00211 10.1016/j.ejphar.2016.05.034 10.1016/j.ejphar.2013.09.052 10.1016/j.jid.2017.01.024 10.1111/bph.13251 10.1016/j.phymed.2013.01.013 10.1111/dom.12317 10.1111/bcp.12131 10.1016/j.amjms.2017.03.023 10.1016/j.mpmed.2018.10.009 10.1016/j.lfs.2014.11.001 10.1152/ajpendo.00639.2012 10.1016/j.psyneuen.2015.08.014 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION DOA |
| DOI | 10.3390/scipharm89010005 |
| DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2218-0532 |
| ExternalDocumentID | oai_doaj_org_article_e95d5426f438406a8194bd747f9e287b 10_3390_scipharm89010005 |
| GroupedDBID | --- 123 2WC 5VS 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AADQD AAFWJ AAYXX ABCQX ABDBF ABOCM ABUWG ACIHN ACUHS ADBBV AEAQA AFKRA AFPKN AFZYC AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BFMQW BPHCQ BVXVI CCPQU CITATION CS3 DIK DU5 E3Z EBD EBS EJD ESX F5P FRP FYUFA GROUPED_DOAJ GX1 HH5 HMCUK IAO KQ8 L7B M1P MK0 MODMG O5R O5S OK1 OVT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO Q2X RNS RPM TR2 TUS UKHRP W2D PJZUB PPXIY PUEGO |
| ID | FETCH-LOGICAL-c351t-cfcab72ca2cfdb5747c6ac4ed156cb8d956107f0221c02c4b24087f7ea8c7e533 |
| IEDL.DBID | DOA |
| ISSN | 2218-0532 0036-8709 |
| IngestDate | Wed Aug 27 01:09:11 EDT 2025 Tue Jul 01 02:40:32 EDT 2025 Thu Apr 24 22:59:06 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c351t-cfcab72ca2cfdb5747c6ac4ed156cb8d956107f0221c02c4b24087f7ea8c7e533 |
| ORCID | 0000-0003-4297-5108 0000-0002-5225-6222 |
| OpenAccessLink | https://doaj.org/article/e95d5426f438406a8194bd747f9e287b |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e95d5426f438406a8194bd747f9e287b crossref_citationtrail_10_3390_scipharm89010005 crossref_primary_10_3390_scipharm89010005 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Scientia pharmaceutica |
| PublicationYear | 2021 |
| Publisher | MDPI AG |
| Publisher_xml | – name: MDPI AG |
| References | Zheng (ref_1) 2018; 14 Stimson (ref_35) 2013; 15 Srinivasan (ref_4) 2019; 47 Hoshiro (ref_15) 2006; 64 Anderson (ref_42) 2016; 101 Cooper (ref_41) 2009; 94 Slominski (ref_18) 2017; 137 ref_11 King (ref_38) 2012; 166 Li (ref_45) 2017; 354 Ye (ref_7) 2017; 60 Oh (ref_12) 2013; 46 ref_19 Schnackenberg (ref_31) 2013; 2013 Andrews (ref_36) 2003; 88 Wright (ref_26) 2013; 76 Park (ref_30) 2014; 52 Heise (ref_25) 2014; 16 Yao (ref_34) 2017; 27 Wang (ref_13) 2011; 203 Byun (ref_5) 2015; 120 Chatzigeorgiou (ref_37) 2009; 23 Yuan (ref_6) 2014; 77 Tiganescu (ref_44) 2013; 123 Hollis (ref_9) 2011; 13 Hong (ref_17) 2018; 835 Bailey (ref_39) 2019; 155 Association (ref_2) 2020; 43 Liu (ref_14) 2013; 2 ref_24 ref_23 Gutierrez (ref_40) 2015; 172 ref_22 ref_43 Rodriguez (ref_10) 2015; 62 Winnick (ref_32) 2013; 304 ref_3 Webster (ref_16) 2013; 20 Park (ref_29) 2013; 721 ref_27 Hamilton (ref_20) 2015; 746 Oh (ref_28) 2015; 768 Anderson (ref_21) 2013; 73 Freude (ref_8) 2016; 18 Yuan (ref_33) 2016; 788 |
| References_xml | – volume: 123 start-page: 3051 year: 2013 ident: ref_44 article-title: 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects publication-title: J. Clin. Investig. doi: 10.1172/JCI64162 – volume: 15 start-page: 37 year: 2013 ident: ref_35 article-title: The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome publication-title: Horm. Mol. Biol. Clin. Investig. doi: 10.1515/hmbci-2013-0015 – ident: ref_24 – volume: 18 start-page: 483 year: 2016 ident: ref_8 article-title: Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: Liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks publication-title: Diabetes. Obes. Metab. doi: 10.1111/dom.12635 – volume: 203 start-page: 127 year: 2011 ident: ref_13 article-title: Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy publication-title: Handb. Exp. Pharmacol. doi: 10.1007/978-3-642-17214-4_6 – volume: 43 start-page: S14 year: 2020 ident: ref_2 article-title: Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020 publication-title: Diabetes Care doi: 10.2337/dc20-S002 – ident: ref_11 – volume: 2 start-page: 133 year: 2013 ident: ref_14 article-title: Clinical safety, pharmacokinetics, and pharmacodynamics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers and elderly adults publication-title: Clin. Pharmacol. Drug Dev. doi: 10.1002/cpdd.5 – ident: ref_27 doi: 10.1186/2050-6511-15-43 – volume: 155 start-page: 107785 year: 2019 ident: ref_39 article-title: The future of new drugs for diabetes management publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/j.diabres.2019.107785 – volume: 13 start-page: 1 year: 2011 ident: ref_9 article-title: 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus publication-title: Diabetes Obes. Metab. doi: 10.1111/j.1463-1326.2010.01305.x – volume: 46 start-page: 567 year: 2013 ident: ref_12 article-title: CREB and FoxO1: Two transcription factors for the regulation of hepatic gluconeogenesis publication-title: BMB Rep. doi: 10.5483/BMBRep.2013.46.12.248 – volume: 2013 start-page: 427640 year: 2013 ident: ref_31 article-title: Chronic Inhibition of 11 β -Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome publication-title: BioMed Res. Int. doi: 10.1155/2013/427640 – volume: 14 start-page: 88 year: 2018 ident: ref_1 article-title: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications publication-title: Nat. Rev. Endocrinol. doi: 10.1038/nrendo.2017.151 – volume: 27 start-page: 4107 year: 2017 ident: ref_34 article-title: Interplay between H6PDH and 11β-HSD1 implicated in the pathogenesis of type 2 diabetes mellitus publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2017.07.043 – ident: ref_23 doi: 10.1002/cpdd.292 – volume: 835 start-page: 169 year: 2018 ident: ref_17 article-title: A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101 publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2018.08.005 – volume: 166 start-page: 877 year: 2012 ident: ref_38 article-title: The use of animal models in diabetes research publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2012.01911.x – volume: 101 start-page: 3787 year: 2016 ident: ref_42 article-title: Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2016-2069 – volume: 64 start-page: 37 year: 2006 ident: ref_15 article-title: Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients publication-title: Clin. Endocrinol. (Oxf.) doi: 10.1111/j.1365-2265.2005.02412.x – volume: 94 start-page: 4645 year: 2009 ident: ref_41 article-title: 11Β-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2009-1412 – ident: ref_22 doi: 10.2427/5768 – volume: 88 start-page: 285 year: 2003 ident: ref_36 article-title: Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2002-021194 – ident: ref_43 doi: 10.1371/journal.pone.0025039 – volume: 746 start-page: 50 year: 2015 ident: ref_20 article-title: Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2014.10.053 – volume: 73 start-page: 1385 year: 2013 ident: ref_21 article-title: 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease publication-title: Drugs doi: 10.1007/s40265-013-0112-5 – volume: 768 start-page: 139 year: 2015 ident: ref_28 article-title: A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2015.10.042 – volume: 52 start-page: 191 year: 2014 ident: ref_30 article-title: A novel 11β-HSD1 inhibitor improves diabesity and osteoblast differentiation publication-title: J. Mol. Endocrinol. doi: 10.1530/JME-13-0177 – ident: ref_3 doi: 10.1016/B978-0-08-102922-0.00004-3 – volume: 77 start-page: 223 year: 2014 ident: ref_6 article-title: Synthesis of novel curcumin analogues for inhibition of 11β-hydroxysteroid dehydrogenase type 1 with anti-diabetic properties publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2014.03.012 – volume: 60 start-page: 4932 year: 2017 ident: ref_7 article-title: Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.7b00211 – volume: 788 start-page: 140 year: 2016 ident: ref_33 article-title: The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2016.05.034 – volume: 721 start-page: 70 year: 2013 ident: ref_29 article-title: Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2013.09.052 – volume: 137 start-page: 1012 year: 2017 ident: ref_18 article-title: Glucocorticoids Inhibit Wound Healing: Novel Mechanism of Action publication-title: J. Invest. Dermatol. doi: 10.1016/j.jid.2017.01.024 – volume: 172 start-page: 4806 year: 2015 ident: ref_40 article-title: Continuous inhibition of 11β-hydroxysteroid dehydrogenase type i in adipose tissue leads to tachyphylaxis in humans and rats but not in mice publication-title: Br. J. Pharmacol. doi: 10.1111/bph.13251 – volume: 20 start-page: 571 year: 2013 ident: ref_16 article-title: Antihyperglycemic and sub-chronic antidiabetic actions of morolic and moronic acids, in vitro and in silico inhibition of 11β-HSD 1 publication-title: Phytomedicine doi: 10.1016/j.phymed.2013.01.013 – volume: 16 start-page: 1070 year: 2014 ident: ref_25 article-title: Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes publication-title: Diabetes, Obes. Metab. doi: 10.1111/dom.12317 – ident: ref_19 – volume: 76 start-page: 917 year: 2013 ident: ref_26 article-title: Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/bcp.12131 – volume: 354 start-page: 408 year: 2017 ident: ref_45 article-title: 11β-Hydroxysteroid Dehydrogenase Type 1 in Obese Subjects With Type 2 Diabetes Mellitus publication-title: Am. J. Med. Sci. doi: 10.1016/j.amjms.2017.03.023 – volume: 47 start-page: 32 year: 2019 ident: ref_4 article-title: Glycaemic management of type 2 diabetes publication-title: Medicine (Baltimore) doi: 10.1016/j.mpmed.2018.10.009 – volume: 120 start-page: 1 year: 2015 ident: ref_5 article-title: A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499 publication-title: Life Sci. doi: 10.1016/j.lfs.2014.11.001 – volume: 23 start-page: 245 year: 2009 ident: ref_37 article-title: The Use of Animal Models in the Study of Diabetes Mellitus publication-title: In Vivo – volume: 304 start-page: E747 year: 2013 ident: ref_32 article-title: Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis publication-title: Am. J. Physiol. Endocrinol. Metab. doi: 10.1152/ajpendo.00639.2012 – volume: 62 start-page: 301 year: 2015 ident: ref_10 article-title: Hypothalamic-pituitary-adrenal axis dysregulation and cortisol activity in obesity: A systematic review publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2015.08.014 |
| SSID | ssj0061417 |
| Score | 2.2811954 |
| SecondaryResourceType | review_article |
| Snippet | Diabetes mellitus is a pathology with increasing frequency in society, being one of the main causes of death worldwide. For this reason, new therapeutic... |
| SourceID | doaj crossref |
| SourceType | Open Website Enrichment Source Index Database |
| StartPage | 5 |
| SubjectTerms | 11β-hydroxysteroid dehydrogenase type 1 inhibitors cortisol glycemic control type 2 diabetes mellitus |
| Title | Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies |
| URI | https://doaj.org/article/e95d5426f438406a8194bd747f9e287b |
| Volume | 89 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NTtwwELYQvXBBbWkFpUVzQEiViHASJ06OUEALEihqoeIW-S-wEkoQyVbaWx-iD9FzH6QPwZMwE2eXFQd66dX5ceQZzXxfPP6Gse3Y6UyoGLkJ8olAGCUDJbkOLOJ9x7kJo17E9ew8HV2K06vkaqHVF9WEeXlgv3B7Lk9sgmmkEjFykVRhBhPaIgiucodoX1P05TmfkSkfgzHnhHIutyt57jcoYyT4dFzmjlShMypM4NS2biEhLej29wnm-DVbHZAh7PsvesOWXP2W7RReWnq6CxdPJ6XaXdiB4kl0errGfp_UN2M9pt450FQQhn__BKOppSIVkkJoxhYO3Q0NoMdg5gIioBCCaqFoOioZwrkP7yfXLSCM9VcjGOplWjgj3c5u0j78_LUP3-bqz-C3FmjGQWD0FlRt4aSG7-MfDRQYT2fjQ8XiO3Z5fHTxZRQMXRgCEydhF5jKKC0joyJTWZ3gyptUGeEsMj-jM0snY7msEAuEhkdGaBJNk5V0KjPSIZp8z5brpnbrDESaujhzOo9NLCKtMiGiKsWogrAUc4beYHszU5RmkCinThm3JVIVMl753Hgb7PP8iTsvz_HCvQdk3fl9JKzdD6C7lYO7lf9ytw__4yWbbCWi0pj-T85HttzdT9wnxDad3mKvDo7Oi69bvTs_Aoj6-xQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibitors+of+11%CE%B2-Hydroxysteroid+Dehydrogenase+Type+1+as+Potential+Drugs+for+Type+2+Diabetes+Mellitus%E2%80%94A+Systematic+Review+of+Clinical+and+In+Vivo+Preclinical+Studies&rft.jtitle=Scientia+pharmaceutica&rft.au=Almeida%2C+Cristiana&rft.au=Monteiro%2C+Cristina&rft.au=Silvestre%2C+Samuel&rft.date=2021-01-01&rft.issn=2218-0532&rft.eissn=2218-0532&rft.volume=89&rft.issue=1&rft.spage=5&rft_id=info:doi/10.3390%2Fscipharm89010005&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_scipharm89010005 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-0532&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-0532&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-0532&client=summon |